GDELT CloudGDELT Cloud
GDELT Agent UIMCPAPIAlerts
PricingDocsEarly Signals
MCPGDELT Cloud Docs MCP
Story clustercameoplus health2026-04-29馃嚦馃嚤

Norgine wins European Commission marketing authorization for mavorixafor in WHIM syndrome

0.22Significance1Articles1Linked events
Top Articles
Norgine B.V.: Norgine announces European Commission Marketing Authorisation for XOLREMDI (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Unionfinanznachrichten.de2026-04-29core
Source Mix
finanznachrichten.de1
Story Quality
Sources
1
Core
1
Events
1
Certainty
0.22
This story is connected to coded event evidence.
Event Map
Story Timeline
No related timeline found for this story yet.
Linked Events
2026-04-29 路 NLD
Vaccine or treatment milestone in Amsterdam
Key Entities
Norgine Norgine0.44
organization 路 14 mentions 路 1 articles
Europe0.02
location 路 6 mentions 路 1 articles
CXCR40.01
other 路 5 mentions 路 1 articles
Committee for Medicinal Products for Human Use0.01
organization 路 4 mentions 路 1 articles
EMA0.01
organization 路 3 mentions 路 1 articles
European Union0.00
location 路 3 mentions 路 1 articles
Australia0.00
location 路 3 mentions 路 1 articles
New Zealand0.00
location 路 3 mentions 路 1 articles
PRNewswire0.00
organization 路 2 mentions 路 1 articles
United States0.00
location 路 2 mentions 路 1 articles
European Commission0.01
organization 路 1 mentions 路 1 articles
https://rarediseases.org/rare-diseases/whim-syndrome/0.00
other 路 1 mentions 路 1 articles
CXCL120.00
other 路 1 mentions 路 1 articles
GDELT CloudGDELT Cloud

Built with GDELT Project data

Explore
ProductPricingSign In
Resources
Early SignalsDocsGDELT Cloud Docs MCP
api reveal 路 v2

API call

Copy any snippet below to fetch the exact same data this page is rendering: no extra params, no transformations.

No API call registered yet on this page.